NeuroMab™ Anti-Notch3 BBB Shuttle Antibody(NRZP-1022-ZP3222)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Immunogen

human Notch3 NRR region

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Humanized

Applications

WB; ELISA; FC; Cyt; In Vitro; In Vivo

Relevant Diseases

Alzheimer's Disease; Epilepsy; Pain

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

Notch3

Official Name

NOTCH3

Full Name

Notch 3

Alternative Names

Notch 3; Neurogenic Locus Notch Homolog Protein 3; Notch (Drosophila) Homolog 3; Notch Homolog 3 (Drosophila); Notch Homolog 3; CADASIL1;

Product Pictures

Figure 1 shows Western blot analysis of Notch3 positive and negative cell lines using the D11B8 antibody.

Figure 2 Intracellular trafficking of anti-Notch3 antibody hu28-DyLight650 and co-localization with pHrodo™ red dextran in MDA-MB-468 breast cancer cells at 8 hours (arrows).

Figure 3 shows Western blot analysis of the S2 cleavage assay using anti-Notch3 hu28 and hu75 treated HCC2429 and MDA-MB-468 cells. MW = molecular weight.

FuncS

Figure 4 shows that treatment of OVCAR3 ovarian cancer cells with anti-Notch3 hu28-vc0101 disrupts microtubules in mitotic cells (stained with anti-α-tubulin antibody), identified by phospho-histone H3 staining.

Figure 5 shows Western blot analysis of Notch3-ECD from xenografts harvested from 2-3 mice (M).

FuncS

Figure 6 shows the efficacy of anti-Notch3 hu28-vc0101 and hu75-vc0101 at a dose of 3 mg/kg compared to cisplatin at a dose of 5 mg/kg in a 37622A1 NSCLC patient-derived xenograft model.